Abstract
425P - Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
Highlights
Irreversible EGFR-tyrosine kinase inhibitors (TKIs) monotherapies showed only moderate efficacy after acquired resistance (AR) to reversible EGFR-TKIs
Six pts obtained partial response and 23 stable disease, resulting in response rate (RR) of 18.8% (95% confidence interval [CI], 7.2-36.4%) and disease control rate of 90.7%
We retrospectively reviewed medical records of patients who had received rebiopsy after completion of the ABC-study: a prospective phase II study of Afatinib (Afa)þBevacizumab (Bev) after acquired resistance to EGFR-TKI
Summary
Irreversible EGFR-TKI monotherapies showed only moderate efficacy after AR to reversible EGFR-TKIs. Third-generation EGFR-TKIs are markedly effective and safe for T790Mþ patients (pts). In randomized controlled trials (RCTs), osimertinib showed encouraging efficacy in patients with advanced EGFR T790M mutation-positive NSCLC; further investigation is needed in the real-world where the patient population is more diverse. This study aimed to assess the effectiveness and safety of osimertinib in a real-world setting. Methods: This observational study enrolled 47 patients with metastatic EGFR T790Mpositive NSCLC who progressed on prior EGFR TKI therapy and commenced osimertinib treatment between May and Oct 2016 in Macau. Conclusions: Real-world physician-assessed RR and PFS with osimertinib appear comparable to that reported in RCTs; no new safety signals were observed. In advanced EGFR-mutant NSCLC, Afa, a second-generation EGFRtyrosine kinase inhibitor (EGFR-TKI) has demonstrated a significant survival benefit over platinum-based chemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
